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Abstract
The term spondyloarthritis refers to a group of immune-mediated diseases
characterised by inflammation of the axial skeleton, peripheral joints, and
entheses. Ankylosing spondylitis (AS) is the most common and characteristic of
these entities and even though it was first described over two centuries ago, the
understanding of the underlying disease mechanism remains incomplete. It is
known that around 40% of patients with AS have subclinical bowel
inflammation, suggesting that the origin of the disease could be in the gut. Also,
more genes and new molecules have demonstrated a role in the pathogenesis
of AS. In this review, we analyse the latest therapies for spondyloarthritis and
the most relevant discoveries over the last three years, together with their
implications for different aspects of the disease.
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Introduction
Ankylosing spondylitis (AS) is a chronic immune-mediated 
inflammatory arthritis included in the so-called group of spondy-
loarthritis (SpA). It typically develops in males in their third 
decade of life and affects mainly the axial skeleton and the sac-
roiliac joints. Although the oldest descriptions date from the 
time of Galen, it was not until the 19th century that the disease 
could be accurately diagnosed on the basis of reports by 
Vladimir Bekhterev, Adolph Strümpell, and Pierre Marie. The 
HLA-B27 allele is known to have a strong association with the 
disease1; however, other genes play a part in its development. 
The discovery of several inflammatory pathways led to the era 
of the biologic therapies, which meant a revolution in the 
treatment and prognosis of AS. Tumour necrosis factor inhibi-
tors (TNFis) were the first ones to be approved, but in the last 
few years the interleukin-17 (IL-17)/IL-23 axis has gained 
relevance, culminating in the licence of new biological disease-
modifying antirheumatic drugs (bDMARDs) blocking IL-17.
In spite of all of these advances, the disease mechanisms 
underlying the disease are not fully understood and new infor-
mation concerning the pathogenesis, triggers, and the outcome 
of new treatments continues to appear. In this review, we will 
focus on the advances of the last three years regarding the above 
aspects of AS.
Genetics
AS is considered an inherited disease, as over 90% of the 
risk for its development relies on genes2. However, the HLA-
B27 allele accounts for only 20% of the genetic effect1. Other 
alleles, especially HLA-B, are thought to play an important role 
in the disease: HLA-B*13:02, HLA-B*40:01, HLA-B*47, and 
HLA-B*51 are some examples3. The most significant discov-
ery of the last three years has been the interaction of ERAP1, 
the protein endoplasmic reticulum aminopeptidase 1, with the 
HLA-B alleles, resulting in a higher risk of developing AS. The 
main variant of the gene (rs30187, K528R) interacts only with 
the HLA-B27 allele, and in patients who are HLA-B27 nega-
tive, ERAP1 interacts with the HLA-B40 allele4. The mechanism 
underlying the increased risk remains unclear; nevertheless, 
it is known that the presence of this gene is not related to the 
radiographic severity of the disease5.
A recent study reported that a lower copy number of the 
TLR7 gene was a marker for susceptibility to AS in males but 
behaves as a protective factor in women6. Ruan et al.7 found 
that genetic polymorphisms of IL-12B (rs6871626) and 
IL-6R (rs4129267) were associated with an increased risk of 
AS independently of gender and also could function as 
biomarkers for diagnosis and prognosis.
Genome-wide association studies have shown that the T helper 
17/23 (Th17/23) axis and its multiple genetic polymorphisms 
are involved not only in AS but also in inflammatory bowel 
disease (IBD) and psoriasis, supporting the hypothesis that 
there is a common underlying pathogenic mechanism and that 
the microbiome seems to be implicated in the development of the 
diseases8.
Pathogenesis
How HLA-B27 initiates AS is unknown, and, after many 
years, some of the earliest hypotheses are still being investi-
gated. The original hypothesis, called the ‘arthritogenic peptide 
theory’, suggests that the presentation of either bacterial peptides 
by HLA-B27 or self-mimicking HLA-B27-binding peptides from 
certain bacteria could initiate a cell-mediated immune reaction 
leading to AS9. The second one is the ‘unfolded protein response’ 
hypothesis, which suggests that HLA-B27 tends to misfold and 
accumulate in the endoplasmic reticulum, triggering a stress 
response that results in the release of IL-2310,11. However, a new 
study12 has questioned these two theories, claiming that the 
arthritogenic peptide theory should be reassessed in terms of 
quantitative changes concerning self-peptide presentation 
and T-cell selection. It also stated that the absolute binding 
preferences of HLA-B27 allotypes are not sufficient to explain 
the association of the disease.
The third hypothesis is the ‘HLA-B27 homodimer model’13, 
which supports the view that HLA-B27 homodimers have an 
abnormal interaction with natural killer (NK) and CD4 T cells. 
Unlike the heterodimeric form of HLA-B27, the homodimer is 
able to bind to certain killer cell immunoglobulin-like receptors 
(KIRs), which are expressed on NK cells and T cells, causing 
the release of IL-1714–16. Ridley et al.17 have proven that CD41 T 
cells upregulate the expression of KIR-3DL2 on the cell surface 
and that the binding of this receptor to HLA-B27 potentiates 
T-cell survival and Th17 cell differentiation. Th17 cells are 
a type of T-helper lymphocyte which produces IL-1718, 
a cytokine able to increase T-cell priming and stimulate immune 
cells such as fibroblasts and macrophages promoting the 
release of IL-6, TNF-α, and other chemokines19.
Oppmann et al. found that IL-23 is one of the triggers of the 
Th17 response20. This molecule is a pro-inflammatory cytokine 
that seems to play an important part in stabilising Th17 cell 
phenotype through the transcription factor Blimp-1 (Prdm1)21, 
which is associated with Crohn’s disease22. Th17 cells are 
commonly found in the intestinal lamina propria of the gut23 
and their instability can be induced by exposure to certain 
bacteria, leading to the transition of Th17 cells into regula-
tory T (Treg) cells24. Maxwell et al.25 also suggested that IL-23 
promotes the accumulation of Treg cells in the bowel, some 
of which probably were Th17 previously26,27.
Microbiome
Gut mucosal inflammation is estimated to be present in 70% 
of patients with AS28, progressing to clinical IBD in 5% of 
cases. Crohn’s disease and ulcerative colitis are characterised 
by having gut dysbiosis (a qualitative or quantitative microbial 
imbalance) which is also seen in AS29. The Ghent inflammatory 
arthritis and spondylitis cohort (GIANT) studies strongly sup-
port the concept that there is a relationship between gut inflam-
mation and the pathogenesis of AS30–32. One of the theories to 
explain it is that a constant antigenic stimulation can activate 
T cells and this might be responsible for chronic bowel 
inflammation33. Other studies suggest that patients with AS 
(and their first-degree relatives) have a high gut permeability, 
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which increases their exposure to gut microbes34. In addition, 
animal studies proved that HLA-B27 alone was insufficient 
to develop AS, since transgenic rats that had been raised in a 
germ-free environment did not develop features of SpA35. In the 
last few years, investigators have focussed on detecting patho-
gens as triggers for AS. Klebsiella pneumoniae was the first to 
be reported36: this bacterium is thought to carry an antigen that 
resembles a molecule coded by the HLA-B27 gene; however, 
the mechanism is not fully understood and other studies have 
stated that its involvement in AS is unlikely. Other relevant fami-
lies of bacteria that have been associated with the development 
of AS are Lachnospiraceae, Prevotellaceae, Rikenellaceae, 
Porphyromonadaceae, and Bacteroidaceae. Non-gut bacteria 
are also thought to be involved: periodontal disease has become 
a possible target as anti-Porphyromonas gingivalis and anti- 
Prevotella intermedia antibodies are detected in high titres in 
patients with SpA37. Some studies even suggest that chronic 
periodontitis is associated with severe spinal dysmobility in 
AS38. Nevertheless, it is still an area of investigation, as 
recently published results contradict these findings39.
Gender differences
Evidence gained in the last few years suggests that AS 
affects men and women differently. Landi et al.40 analysed a 
sample of 2,044 patients with AS and reported that disease com-
mences earlier in men but that the diagnosis is usually more 
delayed than in women. Men have lower disease activity meas-
ured by Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI) and Assessment of SpondyloArthritis international 
Society (ASAS)-endorsed Disease Activity Score (ASDAS) and 
a better quality of life (Ankylosing Spondylitis Quality of Life 
Questionnaire, or ASQol) but have worse spinal mobility (Bath 
Ankylosing Spondylitis Metrology Index, or BASMI) and a more 
serious radiologic progression (Bath Ankylosing Spondylitis 
Radiology Index, or BASRI). In contrast, women usually 
have more peripheral arthritis and an increased prevalence of 
arthritis, dactylitis, and enthesitis combined with a worse qual-
ity of life and a worse response to anti-TNF treatment41. This 
contradicts the results reported by Webers et al.42, who agreed 
that men had more radiographic damage and a better quality 
of life but did not find differences in disease activity or physical 
function. However, the authors analysed only 216 patients.
Therapies
Since 2015, there has been remarkable progress concerning 
the therapeutic management of AS. New treatments and 
strategies have paralleled the description of new pathogenic 
mechanisms. Table 1 summarises the most relevant drugs and 
their mechanism of action; some are still under investigation43–55.
Tumour necrosis factor inhibitors
The first bDMARDs were approved several years ago. As 
the patents of some of these drugs were closer to expiration, 
pharmaceutical companies focused their interest on developing 
more affordable drugs. CT-P13, the infliximab biosimilar, was 
the first one to be released43, followed by Benepali (SB4), the 
etanercept biosimilar, in 201656. Multiple trials endorse the 
similar safety and efficacy of CP-P13 and infliximab not only in 
patients with AS but also in the treatment of rheumatoid arthri-
tis (RA). The PLANETAS study reported comparable results 
for patients with AS regarding ASAS20 and ASAS4057. The 
extension of the study showed that switching from inflixi-
mab to its biosimilar did not imply negative effects on safety or 
efficacy58. These findings were also confirmed in the PLANETRA 
study, carried out in patients with RA59,60. In regard to Benepali 
(SB4), the most important efficacy and safety studies have been 
carried out in RA, showing results similar to those obtained 
with Enbrel44. As far as therapy switching is concerned, the 
Table 1. Novel approaches for the management of ankylosing spondylitis.
Therapy Reference Mechanism of action Current status
CT-P13 
(infliximab biosimilar) 
43 Anti-TNF Approved for use in AS
SB4 
(etanercept biosimilar) 
44 Anti-TNF Approved for use in AS 
Secukinumab 45 Anti-IL-17A Approved for use in AS
Ixekizumab 46 Anti-IL-17A Under investigation. Primary endpoints met.
Brodalumab 47 Anti-IL-17R Not approved owing to safety issues
Ustekinumab 48,49 Anti-IL-12/IL-23 Not approved owing to lack of efficacy
ABT-122 50 Anti-IL-17A/TNF-α Under investigation. Successful phase II clinical 
trials
COVA322 51 Anti-IL-17A/TNF-α Not approved owing to safety issues
CBP30 52 CBP/p300 bromodomain inhibition Future trials announced
Sarilumab 53 Anti-IL-6Rα Not approved owing to lack of efficacy
Tofacitinib 54 JAK inhibitor Under investigation. Successful phase II clinical 
trials
AS, ankylosing spondylitis; IL, interleukin; JAK, Janus kinase; TNF, tumour necrosis factor.
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safety and efficacy are maintained after switching from Enbrel to 
Benepali in patients with RA61, and a study is taking place in 
Germany to assess this transition in patients with AS62.
Interleukin inhibitors
The approval of secukinumab, a fully human monoclonal 
antibody able to neutralise IL-17A, has been a major advance 
in the treatment of AS45. Patients with AS are known to have 
high levels of this interleukin63, which is critically involved in 
the pathogenesis of the disease. IL-23 is secreted by antigen- 
presenting cells and stimulates Th17 cells, which are defined 
by their production of IL-17 cytokines64.
Two double-blind, placebo-controlled, phase III clinical 
trials—MEASURE 165 and MEASURE 266—reported a significant 
improvement in disease activity in patients with AS with effects 
sustained over 2 years; this was combined with a good safety 
profile. Pavelka et al.67 recently published the results of MEAS-
URE 3, a randomised, double-blind, phase III trial in patients 
with active AS. In accordance with previous studies, a significant 
improvement was reported in the 16-week follow-up compared 
with placebo and this was sustained until week 52. The patients 
initially on placebo, who were randomly assigned on week 16, 
also experienced improvement through week 52. During this 
time, no major new adverse events were noted. In addition, 
MEASURE 5, another randomised, double-blind, phase III trial 
is ongoing. It is also comparing the safety and tolerability of 
secukinumab in patients with active AS versus placebo68.
Nevertheless, there are other drugs targeting IL-17. 
COAST-W69 is a phase III, randomised, double-blind, pla-
cebo-controlled trial assessing the effect of ixekizumab on 
radiographic axial SpA. Ixekizumab is also a fully human mono-
clonal antibody that binds to IL-17A. The first results show that 
the drug met all of the primary and secondary endpoints. Broda-
lumab, a monoclonal antibody neutralising IL-17R, proved its 
efficacy for psoriatic arthritis; however, development was paused 
after a higher incidence of suicidal ideation was noted47.
IL-23 is directly related to the development of enthesitis70, 
and the IL-23/IL-17 axis occupies a central place in the patho-
genesis of SpA. Ustekinumab is a human monoclonal antibody 
targeting the p40 subunit of IL-12 and IL-23. It is considered 
one of the most effective treatments for psoriasis71; however, its 
efficacy in AS has not been as expected, and results have been 
contradictory: TOPAS, a prospective, open-label, single-arm, 
proof-of-concept clinical trial72, reported a reduction of signs and 
symptoms in patients with active AS. In contrast, a phase III, 
multicentre, randomised, double-blind, placebo-controlled 
study48 evaluating the efficacy and safety of ustekinumab in the 
treatment of non-radiographic axial SpA had to end prematurely 
after a related study49 did not achieve the key points.
In regard to future approaches, ABT-122, an immunoglobulin 
molecule targeting both IL-17A and TNF-α, has recently 
demonstrated its efficacy in phase I and II trials for RA and 
psoriatic arthritis50,73; however, given the importance of IL-17 
in the pathogenesis of AS, it is expected that trials in patients 
with AS will commence soon. COVA32274 is another dual agent, 
a fusion protein antibody able to bind TNF-α and IL-17A. It was 
thought to be a promising therapy for AS; however, owing to 
safety issues in a trial for psoriatic arthritis, investigations have 
not gone further51. CBP3052 is a selective inhibitor of CBP/p300 
bromodomains able to suppress the production of cytokines by 
Th17 cells in patients with AS and healthy controls. Future trials 
with this molecule have been announced. Sarilumab, a fully 
human monoclonal antibody that blocks the α-receptor of IL-6, 
demonstrated a lack of efficacy for the treatment of AS in the 
ALIGN study53.
Janus kinase inhibitors
Tofacitinib, a Janus kinase (JAK) inhibitor, is also able to inter-
fere in the inflammatory cascade of IL-17, IL-21, and IL-23. In 
a 16-week clinical trial (with 12 weeks of treatment and 4 weeks 
of washout period), van der Heijde et al. reported the superiority 
of the 5 mg dose twice a day versus placebo: 63% and 40% 
of patients, respectively, achieved ASAS20 after 12 weeks54.
An important aspect for biologic therapies is the cost. As 
more patients receive bDMARDs, healthcare systems have been 
forced to find new ways to cope financially: one cost-saving 
strategy is tapering. The 2016 update of ASAS-European League 
Against Rheumatism (ASAS-EULAR) recommendations for the 
management of axial AS75 suggested that patients in sustained 
remission are candidates to taper the dose of the drug. However, 
there is controversy regarding this approach because of conflict-
ing results. One single-centre prospective study76 compared the 
evolution of two groups of patients: one receiving TNFis at the 
standard dose and another group with down-titration. After one 
year of treatment, the clinical outcomes were similar in the two 
arms but costs were significantly reduced in the latter group. 
Plasencia et al.77 previously reported similar results in 
a retrospective study comparing patients in Spain on tapering 
strategy versus patients on standard dose from the Netherlands. 
Even though the proportion of patients who maintained remis-
sion was similar, those in the tapering group had more flares 
than the patients receiving the standard dose. Regarding radio-
graphic progression, Park et al.78 found that patients who had 
syndesmophytes at baseline had a more rapid radiographic 
progression if they received a tapering regime.
Other therapies
bDMARDs are not the only therapies that have been 
developed within the last few years. Fattahi et al.79 reported the 
results of a randomised, placebo-controlled trial of a new non- 
steroidal anti-inflammatory drug (NSAID): B-D-mannuronic 
acid. The 12-week ASAS response was similar to that obtained 
with naproxen, and the safety profile was considerably better; 
there were no renal side effects and gastrointestinal tolerability 
was good.
There has also been controversy regarding the administra-
tion of NSAIDs. Wanders et al.80 reported that continuous 
administration of NSAIDs reduced radiographic progression 
in comparison with on-demand therapy, whereas more recently 
Sieper et al.81 found that continuous treatment with diclofenac 
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for 2 years did not reduce radiographic progression compared 
with an on-demand administration.
Biomarkers
C-reactive protein (CRP) and erythrocyte sedimentation rate 
(ESR) are two acute-phase reactants that classically have 
been used to assess the presence of inflammation in patients. 
Unfortunately, they are not specific and the sensitivity is also 
low82, especially in patients with non-radiographic axial SpA83 
where acute-phase proteins remain within normal limits most of 
the time.
Owing to the lack of a reliable test, many studies have tried to 
find a biologic marker capable of predicting a clinical outcome 
or disease activity in AS. After the discovery of new pathologi-
cal pathways, interleukins became targets. IL-6 was in the spot-
light for some years; but, whereas some studies reported an 
association between IL-6 and disease activity84–86, others 
produced opposite results87,88.
Calprotectin is a dimer of calcium-binding proteins used 
as a surrogate marker for gut inflammation. Its main application 
is monitoring disease activity in IBD89. Both Crohn’s disease 
and ulcerative colitis are known to be associated with AS. The 
pathway is not clear; there are discrepancies concerning whether 
gut inflammation is the cause or the consequence of muscu-
loskeletal disease. Given this, studies have tried to evaluate cal-
protectin for the management of AS. Duran et al.90 found that 
faecal calprotectin was associated with a higher disease activity 
and is a better predictor of bowel involvement than CRP, ESR, 
BASDAI, and Bath Ankylosing Spondylitis Functional Index 
(BASFI). Klingberg et al.91 confirmed these results and also sug-
gested that calprotectin could be used to identify patients with 
AS at high risk of developing IBD. In accordance with this, 
another study92 demonstrated that exercise could decrease the 
levels of calprotectin in patients with AS and that this was 
associated with a reduction of disease activity.
Bone involvement
A typical feature of AS is bone formation co-existing 
with bone resorption. As with many other inflammatory diseases, 
there is an imbalance between these processes, which results in 
the appearance of syndesmophytes and bone erosions in patients 
with AS93. IL-17, one of the most active cytokines in SpA, has a 
major role promoting osteoclastogenesis directly and through the 
activation of receptor activator of nuclear factor kappa B 
(RANK)94,95. However, it does not exert its action alone; it works 
in combination with TNF-α. The latter molecule triggers bone 
destruction through the RANK-RANK ligand (RANK-RANKL) 
system and inhibits bone formation via the overexpression of 
Dickkopf-related protein 1 (DKK1)96, which suppresses the 
WNT bone pathway96,97. WNT/b-catenin signalling is a regula-
tor of osteogenesis and its high levels promote the formation 
of osteoblasts and reduce osteoclastogenesis (and therefore 
bone resorption)98. In contrast to TNF-α, IL-17 has a dual effect 
because it can promote not only bone destruction by acting com-
plementarily with TNF-α99 but also bone formation at sites of 
inflammation or exposed to mechanical stress100. An international 
study101 reported contradictory results, as they found that 
patients with AS had decreased indicators of osteoclast for-
mation and bone resorption, suggesting a reduced capacity of 
osteoclast precursors to differentiate into osteoclasts and 
resorb, probably because of low RANKL/OPG and CD51/CD61 
expression.
Ranganathan et al.102 found that macrophage migration 
inhibitory factor (MIF) was able to act on osteoblasts, promot-
ing inflammation and new bone formation. They also suggested 
that the main source of MIF-producing cells was in the gut and 
that certain pathogens can induce its release. In addition, the 
level of MIF was predictive of progressive spinal damage.
More cytokines are being implicated in the pathogenesis 
of AS. El-Zayadi et al.103 recently reported that IL-22 regulates 
the function of mesenchymal cells, inducing proliferation, migra-
tion, and osteogenesis, in an inflammation-dependent context. 
IL-32γ has been shown to be elevated in the joints and tissues of 
patients with AS and is able to induce osteoblast differentiation 
and atypical new bone formation104. Another interleukin, IL-37, 
is also elevated in patients with osteoporosis in addition to 
AS, and its levels correlate with disease activity and bone min-
eral density105. This is consistent with Kwon et al.106, who found 
that osteoblast-lineage cells are increased in patients with 
AS and are reduced after therapy with infliximab. They also 
reported that the drug allows mature osteoblast differentiation 
in late inflammation.
Machado et al.107 stated that fat deposition in the vertebral 
corners is associated with radiographic progression, and they 
postulated that there should be a ‘window of opportunity’, as 
fat lesions can be preceded by inflammatory lesions. Interest-
ingly, they also found that even though the absence of bone mar-
row oedema and fat deposition was negatively associated with 
radiographic progression, there was still bone formation in 
those areas, implying that there must be other pathways 
stimulating osteoproliferation.
Imaging
The assessment of structural damage is valuable in patients 
with AS. The modified Stoke Ankylosing Spondylitis Spinal 
Score (mSASSS) (which consists of the sum of scores of the 
lumbar and cervical spine from a lateral view, ranging from 0 to 
72) is a commonly used method for detecting changes in plain 
radiographs108; however, X-rays are not a very sensitive tool 
and they are not able to properly differentiate squaring of ver-
tebral bodies. Kim et al.109 evaluated the squaring of the first 
sacral vertebra (S1) by using a method proposed by Ralston 
et al.110: squaring was associated with mSASSS and changes 
in magnetic resonance imaging (MRI) and therefore sug-
gested that this assessment could be used to predict early axial 
involvement of the spine in AS. Regarding other predictors of 
progression, Dougados et al.55 found that HLA-B27-negative 
patients with normal CRP and normal MRI of the sacroiliac 
joints have a 1.2% likelihood of progressing to radiological axial 
SpA within 5 years. This likelihood of progression increased to 
18.4% in HLA-B27-positive patients, with raised CRP and 
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bone marrow oedema in the MRI of the sacroiliac joints. In 
HLA-B27-positive patients, smoking also seems to be asso-
ciated with a proliferative metabolic pattern of the cartilage, 
which could justify its outgrowth and the development of 
enthesopathic lesions111.
Althoff et al. were the first to suggest that contrast was not 
needed to assess axial activity in AS112. However, Zhao et al.113 
confirmed these results by using a large sample of patients, 
showing that the combination of short tau inversion recovery 
(STIR) and diffusion weighted imaging (DWI) in MRI is suf-
ficient to monitor disease activity, avoiding the unnecessary use 
of contrast with its risks. Conversely, Bradbury et al.114 found 
that DWI has a moderate utility for assessing disease activity or 
monitoring response to treatment; however, it seems to be a great 
tool to distinguish axial SpA and non-inflammatory back pain.
Another MRI finding has been the discovery of the ‘backfill 
sign’. It was initially described by Weber et al.115, who defined 
it as a high signal intensity filling the sacroiliac joint space 
on T1-weighted images which could represent fat metaplas-
tic tissue filling excavations in subchondral bone; however, the 
histopathological origin has not been assessed yet. Recently, 
studies confirmed that the ‘backfill sign’ had a high specificity 
for SpA (between 95.8% and 98%)116 but the sensitivity was 
only 59%117. Therefore, its presence could be used to support 
the diagnosis of axial SpA, but its absence should not be used 
to exclude it.
Summary
The numerous investigations and studies carried out within 
the last three years have improved the understanding of the 
pathogenesis of AS. This has facilitated the development of new 
treatment strategies with the consequent improvement of the 
quality life of patients with SpA. As more is known about the 
disease, the greater the complexity that is revealed, emphasis-
ing the need to continue investigation to achieve even more 
efficient control of the disease.
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